MedTech & Diagnostics
RxSight Executive Compensation (FY25)
RXST · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): June 16, 2026
195 figures on this page: 192 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
Ron Kurtz, President, Chief Executive Officer and Director, received $4,650,661 in total compensation for fiscal 2025, and Kurtz's total was 33.4% lower than the $6,982,453 reported for fiscal 2024. Meanwhile, for fiscal 2025, the company reported a chief executive pay ratio of 28:1, against median employee compensation of $164,848. Separately, shareholders supported the say-on-pay proposal with 88.4% of votes cast including abstentions in favor at the meeting held June 16, 2026 for fiscal 2025. For fiscal 2025, the company reported 5 named executive officers.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ron Kurtz: $6,982,453 → $4,650,661 (33.4% lower)
Say-on-pay support: 86.7% → 88.4% (1.7 points higher)
CEO pay ratio: 47:1 → 28:1 (40.4% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is RxSight's chief executive and what were they paid?
Ron Kurtz, President, Chief Executive Officer and Director, received $4,650,661 in total compensation for fiscal 2025. Kurtz's total was 33.4% lower than the $6,982,453 reported for fiscal 2024.
What was RxSight's say-on-pay result?
Shareholders supported the say-on-pay proposal with 88.4% of votes cast including abstentions in favor at the meeting held June 16, 2026 for fiscal 2025.
What is RxSight's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 28:1, against median employee compensation of $164,848.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ron Kurtz Chief Executive Officer, President and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Shelley Thunen Former Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Ilya Goldshleger Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Eric Weinberg Chief Business Development Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ron Kurtz Chief Executive Officer, President and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Ilya Goldshleger Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Shelley Thunen Former Chief Financial Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Eric Weinberg Chief Business Development Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Ron Kurtz President, Chief Executive Officer and Director | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Shelley Thunen Former Chief Financial Officer Departed during or after this year | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Eric Weinberg Chief Business Development Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Ilya Goldshleger Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Scott Gaines Chief Customer Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Eric Weinberg | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ilya Goldshleger | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Ron Kurtz | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Scott Gaines | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Scott Gaines | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Scott Gaines | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Shelley Thunen | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Scott Gaines | Option | ◇ | — | ◇ | 7/30/2035 |
| Option | ◇ | — | ◇ | 2/26/2035 | |
| Option | ◇ | — | ◇ | 8/6/2034 | |
| Option | ◇ | — | ◇ | 3/3/2034 | |
| Option | ◇ | — | ◇ | 3/8/2033 | |
| Option | ◇ | — | ◇ | 3/10/2032 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Ilya Goldshleger | Option | ◇ | — | ◇ | 2/26/2035 |
| Option | ◇ | — | ◇ | 8/6/2034 | |
| Option | ◇ | — | ◇ | 3/3/2034 | |
| Option | ◇ | — | ◇ | 3/8/2033 | |
| Eric Weinberg | Option | ◇ | — | ◇ | 2/26/2035 |
| Option | ◇ | — | ◇ | 8/6/2034 | |
| Option | ◇ | — | ◇ | 3/3/2034 | |
| Option | ◇ | — | ◇ | 3/8/2033 | |
| Shelley Thunen | Option | ◇ | — | ◇ | 2/26/2035 |
| Option | ◇ | — | ◇ | 8/6/2034 | |
| Option | ◇ | — | ◇ | 3/8/2033 | |
| Option | ◇ | — | ◇ | 3/3/2034 | |
| Ron Kurtz | Option | ◇ | — | ◇ | 2/26/2035 |
| Option | ◇ | — | ◇ | 3/8/2033 | |
| Option | ◇ | — | ◇ | 3/3/2034 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Raymond W. Cohen | ◇ | ◇ | — | — | — | — | ◇ |
J. Andy Corley Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Julie B. Andrews | ◇ | ◇ | — | — | — | — | ◇ |
Robert Warner | ◇ | ◇ | — | — | — | — | ◇ |
Juliet Tammenoms Bakker | ◇ | ◇ | — | — | — | — | ◇ |
Robert J. Palmisano | ◇ | ◇ | — | — | — | — | ◇ |
Tamara R. Fountain, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Shweta Singh Maniar | ◇ | ◇ | — | — | — | — | ◇ |
William J. Link, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Ron Kurtz, M.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
| Board meeting fee | ◇ |
| Committee meeting fee | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- Aon, plc AON
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 16, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 3, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 6, 2024 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact RxSight disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where RxSight sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
195 figures on this page: 192 cited to the filing that reported them, 3 calculated from figures it prints.
192 cited to the filing
3 calculated from the filing
Documents cited
- 0001193125-26-272688
- 0001193125-26-187240CEO PAY RATIO DISCLOSURE · Director Compensation · Grants of Plan-Based Awards in 2025 · Outstanding Equity Awards at Fiscal Year-End · and 1 more section
- 0000950170-25-081636
- 0000950170-25-056319Summary Compensation Table
- 0000950170-24-069895
- 0000950170-24-048381Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “RxSight executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/RXST (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about RxSight and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}